<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900676</url>
  </required_header>
  <id_info>
    <org_study_id>VTI/CR&amp;MA/2019/001</org_study_id>
    <nct_id>NCT03900676</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Once or Twice Daily for 12 Weeks in Subjects With Moderate to Severe Inflammatory Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyome Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyome Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in
      the Treatment of Acne Vulgaris,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 2, multicenter, randomized, double-blinded, dose-ranging, parallel arm
      comparison study in male and non-pregnant female subjects, 9 through 45 years of age
      (inclusive) with facial acne vulgaris. This dose-ranging study, intended to identify the
      dose(s), will consist of 7 study visits over 14 weeks:
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple (Participant, Care Provider, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute Change from Baseline in inflammatory lesion counts in each treatment arm at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of Inflammatory Acne (IGA) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of subjects achieving success at Week 12, with success defined as Investigator's Global Assessment of Inflammatory Acne (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from Baseline in inflammatory lesion counts in each treatment arm at Week 12</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>VB-1953 topical gel - 2% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB-1953 topical gel - 2% QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VB-1953 topical gel - 2% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB-1953 topical gel - 2% BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VB-1953 topical gel- 0% (Vehicle) QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VB-1953 topical gel- 0% (Vehicle) QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VB-1953 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VB-1953 topical gel- 0% (Vehicle) BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-1953 - 2%</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>VB-1953 topical gel - 2% BID</arm_group_label>
    <arm_group_label>VB-1953 topical gel - 2% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-1953 - 0% (Vehicle)</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>VB-1953 Vehicle</arm_group_label>
    <arm_group_label>VB-1953 topical gel- 0% (Vehicle) QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females 9 to 45 years of age (inclusive) at the time of
             consent/assent.

          -  Have a clinical diagnosis of moderate to severe (Grade 3 or 4) facial acne vulgaris,
             as determined by the Investigator's Global Assessment (IGA).

          -  Have 20 to 50 inflammatory lesions (papules, pustules) on the face.

          -  Have 20 to 60 non-inflammatory lesions on the face.

        Exclusion Criteria:

          -  Has more than two (2) facial nodulocystic lesions.

          -  Female subject is pregnant, lactating, or is planning to become pregnant during the
             study.

          -  Has active nodulocystic acne or acne conglobata, acne fulminans, or other forms of
             acne (e.g., acne mechanica). In the opinion of the Investigator, the subject has a
             skin pathology or other medical condition that is clinically significant (e.g.,
             obesity) and will preclude participation in the study.

          -  Has presence of any skin condition on the face (e.g., rosacea, dermatitis, psoriasis,
             squamous cell carcinoma, eczema, acnetiform eruptions caused by medications, steroid
             acne, steroid folliculitis, or bacterial folliculitis) in the opinion of the
             Investigator that could interfere with the diagnosis or assessment of acne vulgaris or
             evaluation of the investigational product (IP) or requires the use of interfering
             topical or systemic therapy.

          -  Not willing to minimize or avoid natural and artificial sunlight exposure during
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Shilpi Jain</last_name>
    <role>Study Director</role>
    <affiliation>Vyome Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyome Therapeutics Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79928</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Do not plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

